Context Therapeutics Investor Presentation Deck

CLDN6xCD3 Bispecific Antibody Library Cell Binding (MCF) Bispecific antibodies retain high CLDN6 specificity 30,000- 20,000- 10,000- 0-F -11 Bispecific Formats CLDN9 Reactivity Benchmark (IMAB027) -10 -8 Log [Bispecific] (M) 20 Context Therapeutics Inc. - Sept. 2022 ș Bispecifics induce robust T-cell dependent cytotoxicity % Cytotoxicity 100₁ 50- 0- -3 CLDN6xCD3 Bispecific Antibody Program T-cell Dependent Cytotoxicity -2 -1 1 Log [Bispecific] (nM) 0 H 2 Rucker et al., Development of CLDN6 bispecific antibodies for treatment of ovarian cancer, AACR 2022

View entire presentation